Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05182385 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 25, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 30, 2025 to Apr 30, 2026 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 39 to confirmed 30 · Completion date: Dec 30, 2025 to Apr 30, 2026 · 1 morev4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 39 to confirmed 30
    • Completion date: Dec 30, 2025 to Apr 30, 2026
    • Site details revised at 17 of 17 sites
  2. Primary completion date: Jun 30, 2023 to Jun 30, 2025 Study sites: 7 to 17 · Completion date: Dec 30, 2023 to Dec 30, 2025v3 Show 2 more changesShow less
    • Study sites: 7 to 17
    • Completion date: Dec 30, 2023 to Dec 30, 2025
  3. Study sites: 2 to 7 Eligibility criteria revisedv2 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of Venetoclax and Blinatumomab in in patients with hematological relapse or molecular relapse.
Trial Details
NCT Number NCT05182385
Lead Sponsor Goethe University
Collaborators: University Hospital Schleswig-Holstein
Conditions ALL, Recurrent, Adult
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov